No Data
No Data
China Approves Lukang Pharma's Anti-Asthma Injection
China's medical products administrator approved Shandong Lukang Pharmaceutical's (SHA:600789) doxofylline bronchodilator injection indicated for asthma, according to a Wednesday filing with the Shangh
Lukang Pharmaceutical (600789.SH): Doxofylline injection obtained drug registration certificate
Gelonghui, May 28, 丨 Lu Kang Pharmaceutical (600789.SH) announced that the company's holding subsidiary Shandong Lukang Pharmaceutical Group Saite Co., Ltd. (“SAITE”) has received a “Drug Registration Certificate” (approval number: 2024S00910) for doxofylline injections (referred to as “this drug”) issued by the State Drug Administration. Doxofylline is a novel derivative of methylxanthine. It is a bronchodilator that acts directly on the bronchi to relax bronchial smooth muscle. By inhibiting effects such as phosphodiesterase in smooth muscle cells, it relaxes smooth muscle, thereby suppressing asthma
We Think Shandong Lukang PharmaceuticalLtd (SHSE:600789) Can Stay On Top Of Its Debt
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of permanent loss is the risk I worry about... and every practical investor I know wor
Synthetic organisms are now differentiated! Big bulls have advanced to the 5th straight board, and policy expectations haven't been met yet?
There will be major policies in the future
The top-level file will be released soon! The concept of synthetic biology has risen to prominence, and the pace of industrial development has accelerated
Trillion racetrack
Shandong Lukang Pharmaceutical Co.,Ltd. (SHSE:600789) Looks Inexpensive But Perhaps Not Attractive Enough
With a price-to-earnings (or "P/E") ratio of 21.7x Shandong Lukang Pharmaceutical Co.,Ltd. (SHSE:600789) may be sending bullish signals at the moment, given that almost half of all companies in China
No Data